Mirimus has innovated high-volume COVID-19 PCR testing with SalivaClear™, a two-stage pool-to-diagnostic reflex testing strategy to monitor and detect infection in communities.
A revolutionary, scalable and cost-effective pipeline for the generation of animal models by synergizing RNAi and CRISPR-Cas9 technologies for development of mice, rats, and higher organisms essential for evolving safer and more effective therapeutics.
Harnessing the power of RNAi technologies to develop novel and highly specific treatments for pathological conditions by precisely targeting and silencing genes.
"From the start of the pandemic, it has been Mirimus' mission to provide high-quality RT-PCR testing at a low cost to enable frequent testing of every person, every week, at schools and workplaces."
Prem Premsrirut, MD, PhD
Founder and CEO
